Search
Ripretinib
go.drugbank.com/drugs/DB14840ApprovedInvestigationalRipretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigational(VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles
Rindopepimut
go.drugbank.com/drugs/DB05374InvestigationalThe US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.
Magnesium
go.drugbank.com/drugs/DB14513ApprovedInvestigationalMagnesium is classified as an alkaline earth metal and has 2 hydration shells. The element can be found in abundance in the hydrosphere and in mineral salts such as dolomite and magnesium carbonate. Common dietary sources of magnesium in...
Dicoumarol
go.drugbank.com/drugs/DB00266ApprovedDicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.
Categories: Vitamin K AntagonistsAntrafenine
go.drugbank.com/drugs/DB01419ApprovedIt is not widely used as it has largely been replaced by newer drugs.
Ulevostinag
go.drugbank.com/drugs/DB14721InvestigationalSpecifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T lymphocytes (CTLs). … Upon intratumoral (IT) administration, STING agonist MK-1454 binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear
Tiopronin
go.drugbank.com/drugs/DB06823ApprovedIt is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects.
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Fludiazepam
go.drugbank.com/drugs/DB01567IllicitInvestigationalIt is a scheduled drug in the U.S., but is approved for use in Japan.